Showing results (21-30 of 41) with videos related to

Sort By:
Pageof 5
Cancer Research|March 11, 2026
FET Fusion Oncoproteins Disrupt Physiologic DNA Repair and Create a Targetable Opportunity for ATR Inhibitor TherapyDaniel E Gracilla, Shruti Menon, Marcus R Breese, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|November 4, 2017
Recurrent EML4-NTRK3 fusions in infantile fibrosarcoma and congenital mesoblastic nephroma suggest a revised testing strategyAlanna J Church, Monica L Calicchio, Valentina Nardi, et al.
Molecular Cancer Therapeutics|September 5, 2025
Anti-tumor activity of trastuzumab deruxtecan in pediatric solid tumors with variable HER2 expressionChelsey M Burke, Tamar Y Feinberg, Samantha Brosius, et al.
Genome Medicine|December 24, 2016
Implementation of next generation sequencing into pediatric hematology-oncology practice: moving beyond actionable alterationsJennifer A Oberg, Julia L Glade Bender, Maria Luisa Sulis, et al.
Cancer|June 28, 2024
Roadmap for the next generation of Children's Oncology Group rhabdomyosarcoma trialsJonathan L Metts, Jamie M Aye, Jacquelyn N Crane, et al.
European Journal of Cancer (Oxford, England : 1990)|July 12, 2025
Prioritization of novel agents for further investigation in pediatric non-rhabdomyosarcoma soft tissue sarcomas: A report from the Children's Oncology GroupJacquelyn N Crane, David P Douglass, Sapna Oberoi, et al.
Biorxiv : the Preprint Server for Biology|August 6, 2025
NAPRT expression and epigenetic regulation in pediatric rhabdomyosarcoma as a potential biomarker for NAMPT inhibitionAngela Kim, Prateek Bhardwaj, Collin D Heer, et al.
Cancer Discovery|March 17, 2019
Patient-Driven Discovery, Therapeutic Targeting, and Post-Clinical Validation of a Novel AKT1 Fusion-Driven CancerEmily K Slotkin, Daniel Diolaiti, Neerav N Shukla, et al.
Molecular Cancer Therapeutics|April 22, 2026
NAPRT expression and epigenetic regulation in pediatric rhabdomyosarcoma as a potential biomarker for NAMPT inhibitionAngela Kim, Prateek Bhardwaj, Shahyan Rehman, et al.
JAMA Oncology|October 17, 2024
Lenvatinib Plus Ifosfamide and Etoposide in Children and Young Adults With Relapsed Osteosarcoma: A Phase 2 Randomized Clinical TrialNathalie Gaspar, Giun-Yi Hung, Sandra J Strauss, et al.
Pageof 5